Stryker's OtisMed Pleads Guilty For Selling FDA-Rejected Cutting Guides
This article was originally published in The Gray Sheet
Executive Summary
The unit and its former CEO admitted to selling knee-replacement instruments even after FDA rejected a 510(k), prior to OtisMed being acquired by Stryker in 2009. The legal resolution comes with about $80 million in fines and possible jail time for the former CEO. Also, Stryker has agreed to conduct an audit on the FDA approval status of devices in its portfolio.
You may also be interested in...
Former OtisMed CEO Sentenced To Two Years For Selling FDA-Rejected Knee Devices
The sentencing, which also includes an additional one year of supervised release and a $75,000 fine, concludes a long-running investigation into the firm, which is now a subsidiary of Stryker.
Expert Urges Companies to Heed Whistleblowers
As manufacturers come under more scrutiny for fraud from the federal government, David Marshall, an attorney who specializes in whistleblower cases, says companies that deal with non-compliance issues early are much more likely to get lenient treatment than those who try covering them up.
Expert Urges Companies to Heed Whistleblowers
As device makers come under more scrutiny for fraud from the federal government, David Marshall, an attorney who specializes in whistleblower cases, says companies that deal with non-compliance issues early are much more likely to get lenient treatment than those who try covering them up.